Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
نویسندگان
چکیده
BACKGROUND The heads of the Global Fund and the GAVI Alliance have recently promoted the idea of an international tiered pricing framework for medicines, despite objections from civil society groups who fear that this would reduce the leeway for compulsory licenses and generic competition. This paper explores the extent to which an international tiered pricing framework and the present leeway for compulsory licensing can be reconciled, using the perspective of the right to health as defined in international human rights law. DISCUSSION We explore the practical feasibility of an international tiered pricing and compulsory licensing framework governed by the World Health Organization. We use two simple benchmarks to compare the relative affordability of medicines for governments - average income and burden of disease - to illustrate how voluntary tiered pricing practice fails to make medicines affordable enough for low and middle income countries (if compared with the financial burden of the same medicines for high income countries), and when and where international compulsory licenses should be issued in order to allow governments to comply with their obligations to realize the right to health. An international tiered pricing and compulsory licensing framework based on average income and burden of disease could ease the tension between governments' human rights obligation to provide medicines and governments' trade obligation to comply with the Agreement on Trade-Related Aspects of Intellectual Property Rights.
منابع مشابه
Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
BACKGROUND The recent introduction of Direct Acting Antivirals (DAAs) for treating Hepatitis C Virus (HCV) can significantly assist in the world reaching the international target of elimination by 2030. Yet, the challenge facing many individuals and countries today lies with their ability to access these treatments due to their relatively high prices. Gilead Sciences applies differential pricin...
متن کاملمقایسه نظام قیمت گذاری و بیمه دارو در ایران و کشورهای منتخب
Introduction: Pharmaceuticals comprise a large portion of health care expenditures, including insurance organizations expenditures. Accumulated evidence suggests that the inefficiencies of Iran's health insurance structure have led to soaring out- of- pocket payments by the beneficiaries of health insurance organizations. This study was conducted to compare pricing and reimbursement of pharmace...
متن کاملCompulsory patent licensing and local drug manufacturing capacity in Africa.
Africa has the highest disease burden in the world and continues to depend on pharmaceutical imports to meet public health needs. As Asian manufacturers of generic medicines begin to operate under a more protectionist intellectual property regime, their ability to manufacture medicines at prices that are affordable to poorer countries is becoming more circumscribed. The Doha Declaration on the ...
متن کاملFinding flaws: the limitations of compulsory licensing for improving access to medicines--an international comparison.
متن کامل
Comparison of tiered formularies and reference pricing policies: a systematic review
OBJECTIVES To synthesize methodologically comparable evidence from the published literature regarding the outcomes of tiered formularies and therapeutic reference pricing of prescription drugs. METHODS We searched the following electronic databases: ABI/Inform, CINAHL, Clinical Evidence, Digital Dissertations & Theses, Evidence-Based Medicine Reviews (which incorporates ACP Journal Club, Coch...
متن کامل